Showing 821 - 840 results of 99,256 for search '(( 5 ((026 decrease) OR (a decrease)) ) OR ( 5 ((point decrease) OR (nn decrease)) ))', query time: 1.52s Refine Results
  1. 821
  2. 822
  3. 823

    A tropomyosin point mutant recapitulates the <i>rng8/9</i> deletion phenotype. by Omaya Dudin (3926825)

    Published 2017
    “…(G) Kymographs of Myo52-tdTomato showing multiple stable dots over >60s in <i>cdc8</i><sup><i>E104A</i></sup> mutant. (H) Myo51-3YFP fluorescence at the fusion site is decreased in <i>cdc8</i><sup><i>E104A</i></sup> mutant (N = 15); (***) P < 3 × 10<sup>−5</sup>, t-test. …”
  4. 824
  5. 825

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In contrast, the non-recurrence group demonstrated significant and sustained improvement from 0.31 ± 0.25 preoperatively to 0.25 ± 0.25, 0.23 ± 0.26, 0.23 ± 0.28, 0.21 ± 0.27, 0.20 ± 0.30, and 0.16 ± 0.30 at corresponding postoperative time points (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g005" target="_blank">Fig 5</a>).…”
  6. 826
  7. 827

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…CRT in the recurrence group significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  8. 828
  9. 829
  10. 830

    Shortening of mTL anticipates accumulation of DDR markers, decrease in cell proliferation and increase in apoptotis with age. by Madalena C. Carneiro (102302)

    Published 2016
    “…All tissues show a significant increase in cells bearing five or more γH2AX foci by 12 months of age in <i>tert</i><sup>-/-</sup> zebrafish (panels b, d) and by 36 months in WT zebrafish (panels a, c and e). …”
  11. 831
  12. 832

    <i>In vivo</i> treatment with entinostat decreases Foxp3 expression in Tregs and inhibits Tregs function. by Li Shen (110858)

    Published 2012
    “…Cells were harvested from spleens and lymph nodes. A, <i>In vivo</i> entinostat treatment decreased the expression level of Foxp3 in CD4<sup>+</sup>Foxp3<sup>+</sup> (Treg) cells. …”
  13. 833
  14. 834
  15. 835
  16. 836
  17. 837
  18. 838
  19. 839
  20. 840